Wellth

Wellth

Wellth was founded in 2014 by Matthew Loper and Alec Zopf, emerging from Loper's experience watching family members struggle with chronic disease management. The company operates as a venture-backed digital health firm rather than a traditional family office, selling its adherence platform to managed-care organizations and risk-bearing provider groups. Its technology targets the behavioral side of medication compliance, which public-health researchers have labeled one of the most expensive unsolved problems in American healthcare. The Wellth model is strikingly simple. Members receive a daily financial incentive — typically between $1 and $3 — when they submit a check-in photo showing their prescribed pills in hand. The platform uses computer vision to verify the medication is correct and hasn't been substituted. Payers fund the rewards and pay Wellth a per-member-per-month fee. The company's own published data reports a 40–45% reduction in inpatient admissions among enrolled cohorts, driven primarily by members with congestive heart failure, COPD, diabetes, and other high-cost chronic conditions. Backers include Boehringer Ingelheim Venture Fund, Y Combinator, and several strategic health-plan investors. Funding rounds have been spaced conservatively. Wellth raised a $20 million Series B in 2022 led by SignalFire, with participation from existing investors (per PitchBook, 2022, confirmed via the firm's announcement). As of mid-2025, the company's headcount was estimated at roughly 70 people, with its headquarters in Los Angeles and a secondary presence in New York, though precise team size is not publicly updated. The founding team remains in place — Loper as CEO and Zopf overseeing product and technology — without outside professional management layered on. Structurally, Wellth straddles an unusual boundary between health-tech startup and outcomes-based contracting platform. Its agreements with payers tie fees directly to measured reductions in utilization, making it one of the few digital-therapeutic models that earn revenue only when clinical metrics improve. That risk-sharing architecture distinguishes it from most adherence apps, which charge flat SaaS fees regardless of whether patient behavior actually changes.